Congenital chylothorax means a baby is born with chyle collecting in the space around the lungs, called the pleural space. Chyle is a lymph fluid that carries fats, proteins, and many lymphocytes, which are a type of white blood cell. This condition is rare, but it is the most common cause of pleural effusion in newborns. The fluid may press on one lung or both lungs and make breathing hard.
Congenital chylothorax means a baby is born with leakage of chyle into the space around the lungs. Chyle is a milky body fluid made in the intestines and lymphatic system. It carries fat, proteins, lymphocytes, vitamins, and immune substances. When this fluid leaks into the chest, it can press on the lungs, make breathing hard, reduce oxygen, and cause loss of nutrition and immune cells. It is one of the most common causes of pleural effusion in newborns, but it is still a rare disease.
This condition can become dangerous because the baby may lose large amounts of fluid, protein, albumin, fats, white blood cells, and immunoglobulins into the chest drain or pleural space. That can lead to breathing failure, poor growth, low blood pressure, infection risk, swelling, and long hospital stays. Some babies also have hydrops, lung underdevelopment, heart disease, chromosomal problems, or lymphatic malformations, which can worsen the outcome.
Other names
Congenital chylothorax is also called fetal chylothorax, congenital chylous pleural effusion, neonatal congenital chylothorax, and sometimes primary neonatal chylothorax. Doctors may also describe it under the broader term congenital pleural effusion when the exact fluid type is not yet confirmed.
Types
- Unilateral congenital chylothorax means the chyle is on one side of the chest only. This may still be serious if the fluid is large and presses on the lung.
- Bilateral congenital chylothorax means the fluid is on both sides of the chest. This is often more severe because both lungs can be compressed. In large reviews, bilateral disease was common.
- Prenatally detected congenital chylothorax means the problem is found before birth, usually on fetal ultrasound. It may be seen together with hydrops fetalis, which means fluid collects in more than one body area.
- Postnatally detected congenital chylothorax means the baby is diagnosed after birth, often because of breathing trouble or a pleural effusion seen on chest imaging.
- Isolated congenital chylothorax means it happens by itself without a clear syndrome or other major structural defect. Some babies fall into this group, and in many cases the exact cause is never fully known.
- Syndromic congenital chylothorax means it happens together with a genetic syndrome or another congenital disorder, such as Down syndrome, Noonan syndrome, or Turner syndrome.
or
- Primary or isolated congenital chylothorax: the baby has chylothorax mainly from a developmental lymphatic problem, without another major disease found at first. [4]
- Secondary or associated congenital chylothorax: the chylothorax happens with another condition such as a chromosomal syndrome, lung lymphatic disorder, heart defect, or thoracic duct anomaly. [5]
- Unilateral congenital chylothorax: fluid is mainly on one side of the chest. [6]
- Bilateral congenital chylothorax: fluid is on both sides; this is common in reported newborn cases. [7]
- Prenatally diagnosed type: found during pregnancy by ultrasound. [8]
- Postnatally diagnosed type: found after birth when the baby has breathing trouble or chest fluid. [9]
- Mild type: smaller fluid amount and less effect on breathing. [10]
- Severe type: large fluid amount, lung compression, hydrops, or major nutritional and immune loss. [11]
Causes
1. Thoracic duct developmental defect. The thoracic duct is the main lymph channel. If it forms abnormally, chyle may leak into the chest. [12]
2. Thoracic duct weakness or rupture before birth. Some babies likely develop leakage because the duct wall is fragile or injured during fetal life, even without surgery. [13]
3. General lymphatic dysplasia. This means the lymph vessel network develops in an abnormal way and cannot move lymph normally. [14]
4. Lymphatic malformation. A malformed lymphatic pathway can create blockage or leakage and lead to pleural chyle collection. [15]
5. Congenital pulmonary lymphangiectasia. In this lung-related lymphatic disorder, lymph channels in or around the lungs are abnormally enlarged, and this is one of the most reported associated abnormalities. [16]
6. Pulmonary hypoplasia. Small or poorly developed lungs may be linked with severe fetal pleural effusion and congenital chylothorax. [17]
7. Down syndrome. Trisomy 21 is one of the most common chromosomal conditions reported with congenital chylothorax. [18]
8. Noonan syndrome. This syndrome is strongly linked with lymphatic problems and can be associated with fetal or neonatal chylothorax. [19]
9. Turner syndrome. Turner syndrome can also disturb lymphatic development and has been repeatedly reported in congenital chylothorax. [20]
10. Other chromosomal abnormalities. Reports also describe congenital chylothorax with abnormalities involving chromosomes 13, 14, 2, 7, and 9, among others. [21]
11. Congenital heart disease. Some babies have heart or vessel malformations that may increase venous pressure or disturb lymph return, helping chyle collect in the chest. [22]
12. Arteriovenous malformations. Abnormal blood vessel connections were included among associated congenital heart and vascular findings in published cases. [23]
13. Lymphangiectasia generalisata. This is a more widespread lymphatic disease and can be associated with congenital chylous effusions. [24]
14. Primary hereditary lymphedema. Inherited lymph flow disorders may reflect a deeper lymphatic system problem and may accompany congenital chylothorax. [25]
15. Lymphangiomatosis. This rare disease with diffuse lymphatic channel growth can be linked to chyle leakage. [26]
16. Lymphodysplastic syndrome. Some reports describe syndromic lymphatic dysplasia together with congenital chylothorax. [27]
17. Esophageal or thoracic structural anomalies. Rare thoracic developmental problems can change local anatomy and contribute to lymphatic leakage. [28]
18. Cystic adenomatous malformation of the lung. This rare congenital lung malformation has been listed among associated findings in case reviews. [29]
19. External compression of fetal lymphatics. Some fetal thoracic cavity problems, pressure effects, or masses may disturb lymph drainage and produce primary fetal hydrothorax. [30]
20. Idiopathic cause. In many babies, no single exact cause is proven even after full evaluation, so the condition is called idiopathic or spontaneous congenital chylothorax. [31]
Symptoms
1. Fast breathing. This is one of the most common signs after birth because fluid around the lungs makes breathing difficult. [32]
2. Respiratory distress. The baby may show labored breathing, chest retractions, grunting, or severe trouble expanding the lungs. [33]
3. Low oxygen level. When the lungs cannot open well, oxygen in the blood may fall. [34]
4. Blue lips or skin. Cyanosis can happen if breathing is poor and oxygen is low. [35]
5. Reduced breath sounds. On exam, air entry may be weak on the side with more fluid, or on both sides if the effusion is bilateral. [36]
6. Swollen chest from pleural fluid. A large effusion can make one side or both sides of the chest look fuller than normal. [37]
7. Poor feeding. Sick newborns with breathing difficulty often cannot feed well. [38]
8. Weak cry or tiredness. The baby may look weak because breathing work is high and nutrition loss can be significant. [39]
9. Need for breathing support. Some babies require oxygen, CPAP, or mechanical ventilation very early. [40]
10. Swelling before birth. During pregnancy, fetal edema or hydrops may be seen rather than obvious newborn symptoms. [41]
11. Enlarged abdomen from hydrops or associated fluid. Some fetuses or newborns can have generalized swelling with fluid in more than one body space. [42]
12. Mediastinal shift with severe fluid. Very large pleural collections can push the heart and chest structures to the other side and worsen breathing. [43]
13. Recurrent pleural drainage output. After fluid is drained, it may come back quickly if leakage continues. [44]
14. Signs of malnutrition. Ongoing chyle loss can remove fat, protein, vitamins, and fluid, causing poor growth or weakness. [45]
15. Repeated infections or immune weakness. Chyle contains lymphocytes and immunoglobulins, so long fluid loss can reduce immune protection. [46]
Diagnostic tests
Physical exam tests
1. General inspection. The doctor looks for fast breathing, chest retractions, nasal flaring, cyanosis, and poor activity. This does not prove the diagnosis, but it shows how sick the baby is. [47]
2. Respiratory rate and work of breathing assessment. Counting breaths and looking for distress helps measure the effect of the pleural fluid on the lungs. [48]
3. Chest auscultation. The doctor listens to the chest and may hear decreased breath sounds over the side with fluid. [49]
4. Oxygen saturation check. Pulse oximetry shows whether the baby has low oxygen because the lungs are compressed. [50]
Manual bedside tests
5. Chest percussion. Tapping the chest may suggest pleural fluid because the sound becomes dull over the affected area. This is a classic bedside clue, though it is less precise in tiny newborns than imaging. [51]
6. Assessment of chest movement symmetry. The clinician watches and feels whether both sides of the chest rise equally. Less movement may suggest a larger effusion on one side. [52]
Lab and pathological tests
7. Diagnostic thoracentesis with pleural fluid appearance. A sample of pleural fluid is taken. Chylous fluid is classically milky or opalescent, although it may not look milky in every baby, especially before milk feeding. [53]
8. Pleural fluid triglyceride test. A pleural fluid triglyceride level above 110 mg/dL strongly supports chylothorax in routine practice. [54]
9. Pleural fluid cholesterol test. Chylothorax usually has lower pleural cholesterol, helping separate it from pseudochylothorax. [55]
10. Pleural fluid cell count and differential. Chylous fluid is usually lymphocyte-predominant, often with more than 70% lymphocytes. [56]
11. Chylomicron testing by lipoprotein electrophoresis. Demonstrating chylomicrons in the pleural fluid is the most definitive laboratory proof of chylothorax. [57]
12. Protein, albumin, and electrolyte tests. These blood tests help show how much nutritional and fluid loss the baby has had from ongoing chyle drainage. [58]
Electrodiagnostic or monitoring tests
13. Electrocardiogram, or ECG. ECG does not diagnose chylothorax directly, but it helps assess heart stress, rhythm, and effects of severe thoracic pressure or associated disease. [59]
14. Continuous cardiorespiratory monitoring. Electronic monitoring of heart rate, breathing, and oxygen is important because severe effusions can cause respiratory and hemodynamic compromise. [60]
Imaging tests
15. Prenatal ultrasound. During pregnancy, ultrasound is the key test to find pleural effusion, follow its size, and look for hydrops. Prenatal diagnosis has been reported from 17 to 38 weeks, often around 30 weeks. [61]
16. Postnatal chest X-ray. Chest radiography shows pleural effusion and lung compression, but it cannot by itself prove that the fluid is chyle. [62]
17. Chest ultrasound. Thoracic ultrasound confirms pleural fluid and helps guide safe pleural aspiration or drain placement. [63]
18. Echocardiography. Heart ultrasound is often used to look for associated congenital heart disease and to assess heart function in very sick babies. [64]
19. CT scan or CT lymphangiography. CT can help look for the leak site or for underlying structural causes when the case is complex. [65]
20. Lymphoscintigraphy or MR lymphangiography. These lymphatic imaging tests are used in selected difficult cases to study lymph flow and find the exact site of leakage. [66]
Non-pharmacological treatments
1. Immediate respiratory support. If the pleural fluid is large, the lungs cannot expand well. Babies may need oxygen, CPAP, or mechanical ventilation to keep oxygen levels safe while the fluid problem is being treated. The purpose is to support breathing. The mechanism is simple: reducing lung collapse and improving gas exchange while the chest fluid is drained or controlled.
2. Thoracentesis. This means needle removal of pleural fluid. It is used when fluid is causing severe breathing trouble or when doctors need a sample for diagnosis. The purpose is rapid pressure relief. The mechanism is direct decompression of the chest cavity so the lungs can open better.
3. Chest tube drainage. A chest tube is often needed when fluid keeps coming back. The purpose is continuous drainage and monitoring of output. The mechanism is ongoing removal of chyle, which lowers chest pressure and helps doctors judge whether the leak is improving or worsening.
4. Careful fluid balance monitoring. Babies can lose a lot of body fluid through the chyle leak. The purpose is to prevent shock, dehydration, and organ injury. The mechanism is strict measurement of drain output, urine output, weight, blood pressure, and daily fluid replacement planning.
5. Albumin or colloid replacement strategy. This is supportive rather than curative, but it is often built into non-drug management plans. The purpose is to replace protein losses and maintain circulation. The mechanism is restoring oncotic pressure after major pleural losses.
6. Nil per os, or temporary bowel rest. Some babies are kept off enteral feeds for a time. The purpose is to reduce chyle production. The mechanism is lowering intestinal fat absorption and lymph flow through the thoracic duct so the leak can slow down.
7. Total parenteral nutrition. TPN gives nutrition directly into the bloodstream when enteral feeding needs to stop. The purpose is to maintain calories, protein, and growth while reducing lymph flow from the gut. The mechanism is bypassing the intestinal fat-lymph pathway that normally generates chyle.
8. Medium-chain triglyceride feeding. When feeds are restarted, MCT-rich formulas are commonly used. The purpose is to provide fat calories with less chyle formation. The mechanism is that medium-chain fats are absorbed more directly into the portal blood rather than strongly loading the intestinal lymphatics like long-chain fats do.
9. Long-chain fat restriction. Standard milk fat can increase lymphatic flow. The purpose is to reduce leak volume. The mechanism is reducing the intestinal formation of chylomicrons, which are a major part of chyle production after feeding.
10. Gradual refeeding protocol. Feeding is often restarted slowly after the output improves. The purpose is to avoid reopening the leak. The mechanism is stepwise increase in enteral nutrition while watching drainage, breathing, and abdominal tolerance.
11. Serial chest imaging. Repeated X-rays or ultrasound help track response. The purpose is to know whether fluid is shrinking or returning. The mechanism is visual monitoring so clinicians can adjust drainage, feeds, and escalation decisions early.
12. Immune monitoring. Because chyle contains lymphocytes and immunoglobulins, immune losses can be large. The purpose is infection prevention and timely immune support. The mechanism is repeated blood tests for lymphocyte counts and immunoglobulin levels.
13. Infection-control care. Babies with drains, TPN lines, and immune losses are vulnerable to infection. The purpose is to reduce sepsis risk. The mechanism is strict line care, sterile drain care, hand hygiene, and close monitoring for fever or deterioration.
14. Prenatal fetal intervention in selected cases. In severe fetal cases with large effusions or hydrops, fetal thoracentesis or thoracoamniotic shunting may be considered before birth. The purpose is to reduce compression of the fetal lungs and heart. The mechanism is prenatal decompression to improve development and survival.
15. Multidisciplinary lymphatic team review. Persistent cases may need neonatology, surgery, cardiology, genetics, interventional radiology, and nutrition together. The purpose is better problem-solving in rare disease. The mechanism is combining expertise for anatomy, syndromic causes, and advanced interventions.
16. Genetic evaluation. Some babies have associated syndromes or lymphatic-development disorders. The purpose is to identify the cause and guide prognosis. The mechanism is chromosomal and gene testing when the history or exam suggests a syndromic pattern.
17. Cardiac assessment. Congenital heart disease or raised venous pressure may worsen lymphatic leakage. The purpose is to detect contributing circulatory problems. The mechanism is echocardiography and hemodynamic assessment.
18. Skin, growth, and nutrition surveillance. These babies can lose calories and protein fast. The purpose is to avoid malnutrition and poor recovery. The mechanism is regular weight checks, edema assessment, serum protein review, and nutrition adjustment.
19. Family education. Parents need simple teaching about drain output, breathing signs, feeding plans, and infection warning signs. The purpose is safer care and less anxiety. The mechanism is shared understanding, earlier reporting of problems, and better adherence after discharge.
20. Surgical or interventional planning when conservative care fails. Non-drug care still includes deciding when to escalate. The purpose is leak control in refractory disease. The mechanism is moving from supportive management to definitive procedures such as duct ligation or pleurodesis when drainage remains high.
Drug treatments and supportive medicines
1. Octreotide. This is the best-known medicine used for neonatal chylothorax, but it is off-label for this purpose. It is a somatostatin analogue. The purpose is to reduce lymph production and help the leak close. The proposed mechanism is reduction of splanchnic blood flow, intestinal absorption activity, and lymphatic flow. Dosing in reports varies widely, often by continuous infusion with stepwise increase. Important side effects reported in neonates include blood sugar changes, cholestasis, thyroid effects, gut ischemia concerns, and possible pulmonary hypertension, so close NICU monitoring is necessary.
2. Somatostatin. Some centers use somatostatin rather than octreotide. The purpose is similar: lowering chyle production. The mechanism is hormonal suppression of gastrointestinal secretions and reduction of lymph flow. This is also off-label in congenital chylothorax and mainly supported by case reports and small series, not large randomized neonatal trials.
3. Human albumin infusion. This does not seal the leak, but it treats heavy protein loss. The purpose is correction of low albumin, edema, and poor circulatory filling. The mechanism is restoration of plasma oncotic pressure so fluid stays in the blood vessels better. It is considered when ongoing drainage causes hypoalbuminemia or hemodynamic instability.
4. Intravenous immune globulin. IVIG may be used when immunoglobulin loss becomes clinically important. The purpose is immune support in babies losing antibodies through chyle. The mechanism is passive replacement of immunoglobulins, especially when lab tests show low levels and infection risk is high.
5. Furosemide. This is not a chyle-stopping drug, but it may be used if there is edema or pulmonary fluid overload. The purpose is fluid off-loading. The mechanism is loop diuresis in the kidney. It must be used carefully because these babies can also be intravascularly depleted from drain losses.
6. Sildenafil. Some babies with congenital chylothorax also have pulmonary hypertension. In that setting, sildenafil may be used for the lung circulation problem, not for the chyle leak itself. The purpose is lowering pulmonary vascular resistance. The mechanism is phosphodiesterase-5 inhibition and nitric oxide pathway support.
7. Milrinone. In babies with cardiac dysfunction or significant hemodynamic compromise, milrinone may be used as ICU support. The purpose is improving cardiac output and reducing afterload. The mechanism is phosphodiesterase-3 inhibition with inotropic and vasodilator effects. This is supportive treatment only.
8. Norepinephrine. If severe hypotension develops, norepinephrine may be required. The purpose is blood pressure support. The mechanism is vasoconstriction and maintenance of perfusion in shock states. This is not disease-specific and is only for unstable patients under intensive monitoring.
9. Epinephrine. Epinephrine can also be used in selected critically ill babies with severe cardiovascular instability. The purpose is emergency blood pressure and cardiac support. The mechanism is alpha and beta adrenergic stimulation. This is rescue support, not standard disease therapy.
10. Fentanyl. Some ventilated or drained neonates need analgesia and sedation. The purpose is pain control and ventilator tolerance. The mechanism is opioid receptor activation. The risk is respiratory depression and opioid-related adverse effects, so it is strictly NICU-supervised.
11. Morphine. Morphine may be used similarly for analgesia and sedation. The purpose is comfort and reduced stress in babies with chest tubes or ventilation. The mechanism is opioid analgesia. It must be used cautiously because neonatal respiratory drive is fragile.
12. Antibiotics when infection is suspected. Antibiotics do not treat the leak, but they are important if line infection, pneumonia, or sepsis is suspected. The purpose is infection control. The mechanism depends on the antibiotic chosen, and selection is based on culture data and local NICU practice.
13. Surfactant in selected premature babies. If the infant also has surfactant deficiency or severe respiratory distress syndrome, surfactant may be used. The purpose is better lung compliance. The mechanism is lowering alveolar surface tension. It treats associated lung disease, not the lymphatic leak.
14. Propranolol. This is not routine care, but case-based lymphatic-disorder practice has explored propranolol in selected abnormal lymphatic flow conditions. The purpose is possible modulation of lymphatic abnormalities in special cases. The mechanism is uncertain and evidence is weak for congenital chylothorax alone.
15. Sirolimus. Sirolimus is not standard first-line therapy for ordinary congenital chylothorax, but targeted use is emerging in complex central lymphatic anomalies. The purpose is control of abnormal lymphatic growth or signaling. The mechanism is mTOR pathway inhibition. It belongs to specialist-center care only.
16. Corticosteroids. Steroids are not routine first-line therapy for uncomplicated congenital chylothorax, but they may be considered in selected inflammatory or associated conditions. The purpose is inflammation control. The mechanism is broad anti-inflammatory and immunosuppressive action. Evidence is limited for direct leak closure.
17. Electrolyte replacement agents. Sodium, potassium, calcium, magnesium, and phosphate replacement may be needed because large pleural losses and TPN therapy can disturb the internal balance. The purpose is metabolic stability. The mechanism is direct correction of biochemical deficits.
18. Vitamin replacement during prolonged fat restriction or TPN. Fat-soluble vitamin support may be needed. The purpose is prevention of deficiency during prolonged low-fat feeding. The mechanism is replacement of nutrients that may be poorly absorbed or lost.
19. Packed red cells when anemia develops. Blood loss from repeated sampling or critical illness may require transfusion. The purpose is oxygen-carrying support. The mechanism is direct increase in hemoglobin. This is supportive ICU care.
20. Targeted molecular therapy in rare lymphatic syndromes. In very unusual infants with defined lymphatic disorders, highly specialized targeted therapy may be considered. The purpose is disease-modifying control of abnormal lymphatic biology. The mechanism depends on the mutation or pathway involved. This is investigational or specialist-center medicine, not standard routine neonatal chylothorax treatment.
Dietary molecular supplements
For this disease, supplements are usually part of a medical nutrition plan, not home treatment. Helpful nutritional supports can include MCT-based fat sources, essential fatty acid supplementation when long-chain fat is heavily restricted, protein supplementation, fat-soluble vitamins A, D, E, and K, zinc, selenium, iron if deficient, and trace-element balancing within TPN. Their purpose is to prevent malnutrition while the chyle leak is being reduced. The mechanism is replacement of nutrients lost in chyle or reduced by strict fat modification. Exact doses depend on age, weight, blood tests, and whether the baby is on TPN, breast milk modification, or special formula.
Regenerative, immunity, or stem-cell related drugs
There is no standard FDA-approved stem-cell drug for routine congenital chylothorax. In practice, the main “immune support” medicine is IVIG when immunoglobulin loss is important. In rare lymphatic anomaly cases, sirolimus and other specialist-targeted therapies may be used, but these are not routine newborn treatments for typical congenital chylothorax. So the honest evidence-based answer is that this category is very limited for this disease. Claims of established regenerative or stem-cell medicines for routine congenital chylothorax would not be accurate.
Surgeries or procedures
The main procedures are thoracentesis, chest tube placement, thoracic duct ligation, pleurodesis, and in selected advanced centers lymphatic embolization or image-guided lymphatic intervention. These are done when breathing is compromised, output stays high, or conservative treatment fails. Their purpose is either to remove pressure from the chest or to stop the leak more definitively.
Prevention points
True prevention is difficult because the condition is congenital. Still, risk reduction includes good prenatal ultrasound follow-up, referral of severe fetal cases to tertiary centers, planned delivery where NICU and pediatric surgery are available, rapid postnatal diagnosis, early drainage when needed, careful line care, safe nutrition protocols, monitoring immune losses, avoiding uncontrolled refeeding, and early specialist referral for persistent leaks. These steps do not stop the malformation from existing, but they can reduce complications and improve survival.
When to see a doctor urgently
A baby needs urgent medical care for fast breathing, chest retractions, blue lips, poor feeding, vomiting, fever, reduced activity, low urine, increasing swelling, drain output rising again, or sudden oxygen need. Families should not try diet changes, supplements, or medicines at home without neonatal specialist advice, because the disease can worsen quickly and treatment must be individualized.
What to eat and what to avoid
For newborn congenital chylothorax, feeding is not a general home diet issue; it is a doctor-directed neonatal nutrition plan. The usual helpful approach is MCT-based feeds or carefully modified feeding plans when enteral nutrition is allowed. What to avoid is unplanned standard high long-chain-fat feeding, because that can raise chyle production. During severe leaks, the baby may need temporary bowel rest with TPN instead of milk feeds.
FAQs
What is congenital chylothorax? It is lymphatic fluid collecting around the lungs from birth. Is it rare? Yes, rare but clinically important. Can it cause breathing failure? Yes. Is the fluid always milky? Often after feeding starts, but not always early. Is octreotide a cure? No, but it may help reduce leakage. Is octreotide FDA-approved for this disease? No, it is generally off-label here. Do all babies need surgery? No, many improve with conservative care. Can the baby lose immunity? Yes, because lymphocytes and immunoglobulins can be lost. Is feeding important? Extremely important. Why use MCT? It usually produces less lymphatic fat flow than long-chain fats. Can the disease come with syndromes? Yes. Is prenatal treatment possible? In selected severe fetal cases, yes. Can it come back? It can persist or recur depending on the cause. Is long hospital care common? Yes, especially in complicated cases. What improves outcome most? Early diagnosis, respiratory support, smart drainage, nutrition control, and specialist care.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 12, 2025.
